Physician profile
Fawad Malik
NPI 1689788283
$1,961.00
in general payments reported to CMS, 2019-2025
14 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $157 · 2021: $296 · 2022: $574 · 2023: $285 · 2024: $371 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $380.58 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.43 | 2021-2024 | Caplyta |
| Lundbeck LLC | $244.96 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $241.81 | 2022-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $238.78 | 2021-2024 | |
| Axsome Therapeutics, INC. | $138.53 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $81.29 | 2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $65.13 | 2023 | Dyanavel Xr |
| Alfasigma USA, INC. | $52.82 | 2022 | |
| Corium, LLC | $49.54 | 2022 | |
| Alkermes, INC. | $49.12 | 2024 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $46.86 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $18.03 | 2019 | |
| Orexo US, INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fawad Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.